Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition
Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.
Revvity bought a company that helps discover new diabetes and weight-loss medicines, betting that these drugs will be super popular. When companies spend money to get better at what customers want, it can be a sign they think their business will grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.